In this weekly superstock scan, I was unable to find any new superstock candidate .  I initially thought I have found one -  SciClo...

Weekly Superstock Scan 18 Apr 2016 - 22 Apr 2016: Nil

/
0 Comments
In this weekly superstock scan, I was unable to find any new superstock candidate



I initially thought I have found one - SciClone Pharmaceuticals (SCLN), and was about to blog about it. It has a nice breakout from a long flat base (with the exception of a few fake out), new marketing strategies and a new potential blockbuster product. Digging deeper, I found that SciClone has engaged Lazard as its financial advisor to assist the Board in evaluating strategic alternatives.

According to Jesse Stine, "strategic alternatives" is a sell signal. Although it is a fancy way of saying that they are putting themselves up for sale, most of the announcements ends up as a secondary offering or bankruptcy. On 12 April, SCLN filed a confidential treatment order which fueled more speculations of a buyout. The future of SCLN is too uncertain to be a potential superstock.

===============================================================

Previous Superstocks


EXFO (Posted on 10th Apr 2016 Watchlist)
Fall away from low risk entry point, pending pullback.

BORN (Posted on 3rd Apr 2016 Watchlist)
Waiting for pullback at 30wMA with low volume and range

ELMD (Posted on 3rd Apr 2016 Watchlist)
Entered at 4.2 this week

PLPM (Posted on 27th Mar 2016 Watchlist)
Missed a low-risk entry point and price took off

SNC (Posted on 6th Mar 2016 Watchlist)
Very close to entry at 10wMA.

JRJC (Posted on 14th Feb 2016 Watchlist)
Looking to buy at upward trendline and 10wMA in the 4.90 region. 

EDUC (Posted on 24th Jan 2016 Watchlist)
Entered @ 9.95.

VRA (Posted on 11th Jan 2016 Watchlist)
Entered @ 14.4 and Exited at 17.25. May re-enter at 20wMA.


You may also like

No comments:

Powered by Blogger.

Disclaimer

All information in The Trader Diaries (TTD) does not constitute to investment advice or recommendation to buy, sell or hold. Readers are advised to consult their financial advisors prior to making any investment or pursuing any investment strategy. TTD will not be liable for any losses resulted from information published or shared from the blog.